ArticleFood science & nutrition2026
Hederagenin Promotes Sorafenib Sensitivity in Hepatocellular Carcinoma Through Suppressing SLC7A11 Expression and Inducing Ferroptosis.
Article in Food science & nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sorafenib (SOR) significantly improves the survival rate for patients with advanced hepatocellular carcinoma (HCC). Nevertheless, the clinical efficacy is restricted by the development of acquired resistance. Therefore, enhancing susceptibility of HCC cells to SOR is of critical importance for patients with advanced disease. Traditional Chinese medicine (TCM) possesses considerable potential to overcome SOR resistance. Hederagenin (HED), a bioactive triterpenoid molecule with potent antitumor activity, has been reported to markedly reduce chemoresistance to various anticancer drugs in cancer cells. In the present study, we observed that HED synergistically potentiated the anticancer activity of SOR in HCC cells, reducing its IC50 by more than 50%. Further investigations revealed that HED increased SOR-induced ferroptosis, and inhibition of ferroptosis clearly abrogated this synergistic effect. Mechanistically, SLC7A11, a key regulator of ferroptosis, was identified as a potential target of HED in HCC. And our data further revealed the pronounced upregulation of SLC7A11 in human HCC tissues, whereas HED treatment significantly downregulated its expression, suggesting that SLC7A11 might be a principal molecular target of HED in SOR-mediated ferroptosis. Furthermore, loss- and gain-of-function experiments confirmed that SLC7A11 plays an essential role in mediating HED-enhanced SOR-induced ferroptosis. In summary, our results demonstrated that HED synergistically promoted the anti-cancer effects of SOR on HCC cells by suppressing SLC7A11 expression, thereby triggering ferroptosis. These results suggest that HED represents a promising strategy to overcome SOR resistance and offers a viable therapeutic approach to improve SOR efficacy in patients with resistant HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.